Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Plasma Fractionation Market Expansion From $37.62 Billion In 2026 To $55.85 Billion In 2030
The value of the plasma fractionation market has experienced considerable expansion in recent years, increasing from $34.14 billion in 2025 to $37.63 billion in 2026, which reflects a compound annual growth rate (CAGR) of 10.2%. This historical growth has been primarily driven by a heightened demand for immunoglobulins, a growing incidence of hematological disorders, progress in plasma fractionation technology, the development of healthcare facilities such as hospitals and clinics, and greater public awareness of therapies derived from plasma.
The plasma fractionation market is anticipated to experience significant expansion in the coming years, with projections indicating it will reach $55.85 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.4%. This forecasted growth is fueled by factors such as the rising uptake of precision medicine, the incorporation of artificial intelligence into plasma manufacturing processes, the growth of worldwide biopharmaceutical partnerships, increased funding for plasma collection facilities, and the creation of innovative plasma-derived treatments. Key developments shaping this period include the emergence of sophisticated plasma fractionation methods, a broader range of biopharmaceutical offerings, stricter quality assurance and regulatory adherence, the growth of contract manufacturing organizations (CMOs/CDMOs), and improvements in the supply chain for plasma-based products.
Download A Free Sample Report For Comprehensive Market Insights:
Plasma Fractionation Market Demand Drivers: What Is Fueling Industry Growth?
The rising prevalence of chronic conditions is anticipated to drive expansion in the plasma fractionation market moving forward. Chronic diseases are characterized as health issues lasting a year or more, demanding continuous medical care, with examples including heart disease, cancer, and diabetes. Managing patients with these conditions through access to plasma-derived products reduces illness rates, enhances life quality, and offers cost-effectiveness, consequently boosting the need for plasma fractionation. For example, in March 2025, GOV.UK, a non-profit UK government entity, reported that general practitioners recorded type 2 diabetes prevalence at 7.0% among adults aged 17 and over in England in March 2024, up from 6.8% in March 2023. As a result, a growing number of chronic diseases across all age groups is expected to foster plasma fractionation market growth.
Plasma Fractionation Market Segmentation: How Is The Market Structured Across Key Categories?
The plasma fractionation market covered in this report is segmented –
1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors
2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology
3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes
Subsegments:
1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)
3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)
4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)
Plasma Fractionation Market Innovation Trends: Which Developments Are Transforming The Industry?
Major players in this sector are rolling out innovative technologies, such as state-of-the-art facility processes that convert donated human plasma into vital medications, leveraging advanced systems to boost both efficiency and safety. For example, in March 2023, CSL Behring, a firm based in Germany, launched a new plasma fractionation facility valued at $470 million. This plant employs cutting-edge technology to enhance the effectiveness and security of plasma processing, thereby ensuring the production of higher-quality and more dependable medicines. By expanding the availability of these essential treatments, the facility addresses the increasing demand, allowing a greater number of patients to access life-saving therapies. Through the use of sophisticated automation and self-cleaning mechanisms, it minimizes contamination risks and elevates hygienic standards, ultimately strengthening patient safety.
Plasma Fractionation Market Competitive Landscape And Leading Companies
Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP
Access The Complete Plasma Fractionation Market Report:
Plasma Fractionation Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model